Objective: Explore the association between Parkinson’s disease (PD) and osteoporosis (OP).
Background: In recent years, PD and OP have emerged as significant global public health burdens[1, 2]. Increasing attention has been directed toward the association between these two conditions[3]. In response to this research focus, this study conducted a bibliometric analysis and explored the molecular mechanisms to investigate global research trends, shared molecular mechanisms, and the clinical significance of PD and OP.
Method: Literature published between 2001 and 2025 was retrieved from the WOSCC, PubMed, and Scopus databases. Bibliometric and visualization analyses were performed using specialized software. Disease-related genes and pathways were explored through GeneCards and STRING databases, and key genes were externally validated using GEO datasets via receiver operating characteristic (ROC) curve analysis.
Results: A total of 173 articles met the inclusion criteria. Publication output on PD and OP has steadily increased in recent years, with China as the leading contributor. Core keywords such as “falls,” “fracture,” and “Alzheimer’s disease” reflect current research focus and trends. Bioinformatics analysis identified 211 intersecting genes between the two diseases, with MAPK3, JUN, and PRKACB highlighted as representative targets. The underlying mechanisms primarily involve cell survival and apoptosis-related signaling pathways, as well as metabolism- and vascular-related pathways, including the MAPK, PI3K-Akt, and AGE-RAGE signaling pathways. ROC analysis validated the diagnostic potential of MAPK3, JUN, and PRKACB, further supporting their prospective clinical relevance in PD and OP.
Conclusion: Both bibliometric and bioinformatics analyses revealed a close and potential association between PD and OP. The two diseases share 211 intersecting genes, with MAPK3, JUN, and PRKACB as key targets involved in cell survival, apoptosis, metabolism, and vascular-related pathways. ROC analysis confirmed their diagnostic potential, highlighting clinical relevance. These findings provide new insights into shared pathogenic mechanisms and offer a foundation for the development of biomarkers and combined therapeutic strategies.
References: 1. Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284-303.http://dx.doi.org/10.1016/S0140-6736(21)00218-X.
2. Ye C, Ebeling P, Kline G. Osteoporosis. Lancet. 2025;406(10514):2003-16.http://dx.doi.org/10.1016/S0140-6736(25)01385-6.
3. Wadood LA, McHugh V, Clemens KK, Jenkins ME, Holmes JD, Fleet JL. Management of osteoporosis in Parkinson’s disease: A scoping review. Bone. 2026;202:117646.http://dx.doi.org/10.1016/j.bone.2025.117646.
To cite this abstract in AMA style:
L. Xiao, J. Fan, Y. Wu, K. Liao, L. Zhuang. Parkinson’s Disease and Osteoporosis Comorbidity: A Bibliometric Analysis and Exploration of Mechanistic Pathways and Key Genes [abstract]. Mov Disord. 2026; 41 (suppl 1). https://www.mdsabstracts.org/abstract/parkinsons-disease-and-osteoporosis-comorbidity-a-bibliometric-analysis-and-exploration-of-mechanistic-pathways-and-key-genes/. Accessed October 1, 2026.« Back to 2026 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/parkinsons-disease-and-osteoporosis-comorbidity-a-bibliometric-analysis-and-exploration-of-mechanistic-pathways-and-key-genes/